Skip to main content

Treatment Clinical Trials for Breast Neoplasm

Review the breast neoplasm treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 351-375 of 475

ALG.APV-527 First-in-human Study
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Tivozanib and Atezolizumab for the Treatment of Advanced, Unresectable, or Metastatic Immunologically Cold Tumor Types
Status: Active
Location: UF Health Cancer Institute - Gainesville, Gainesville, Florida
Personalized Neoantigen Peptide-Based Vaccine in Combination with Pembrolizumab for the Treatment of Advanced Solid Tumors, The PNeoVCA Study
Status: Active
Location: Mayo Clinic in Florida, Jacksonville, Florida
Muse Magnetic Resonance Guided Focused Ultrasound System for the Treatment of Breast Cancer
Status: Active
Location: Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah
Focused Ultrasound with Low-Dose Gemcitabine to Increase Immune Control in Patients with Stage I-III Breast Cancer
Status: Active
Location: University of Virginia Cancer Center, Charlottesville, Virginia
Pre-operative Radiation Therapy for the Treatment of Females with Early Stage Biologically Favorable Breast Cancer
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Breast Radiotherapy (SABER) for the Treatment of Hormone Receptor Positive HER2 Negative Early Stage Breast Cancer
Status: Active
Location: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer
Status: Active
Location: Mayo Clinic in Rochester, Rochester, Minnesota
A Study to Assess CLBR001+ABBV-461 in Subjects With Locally Advanced or Metastatic Breast Cancer
Status: Active
Location: Roswell Park Cancer Institute, Buffalo, New York
A Combined Vaccine (MVF-HER-2 [597-626] and MVF-HER-2 [266-296]) for the Treatment of Metastatic or Unresectable Breast or Gastrointestinal Cancer
Status: Active
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
Adoptive T-Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine, Pepinemab and Trastuzumab for the Treatment of HER2 Positive Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Dendritic Cell Vaccine in Combination with Elacestrant for the Treatment of ESR1-Mutated, Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Genetically Engineered Cells (iC9-CAR.B7-H3 T cells) for the Treatment of Patients with Relapsed or Refractory Triple Negative Breast Cancer
Status: Active
Location: UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina
Avasopasem for the Treatment of Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer with Progression on a CDK4/6 Inhibitor and Hormonal Therapy
Status: Active
Location: Cancer Therapy and Research Center at The UT Health Science Center at San Antonio, San Antonio, Texas
Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
HER2 and HER3-Directed Dendritic Cell Vaccine for the Treatment of Early Stage Triple Negative or Hormone Receptor Low Breast Cancer, The DecipHER Trial
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
A Vaccine (MUC1 Peptide-Poly-ICLC) for the Treatment of Estrogen Receptor Positive Breast Ductal Carcinoma in Situ
Status: Active
Location: University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania
Leflunomide for the Treatment of PTEN-Altered Advanced Solid Tumors and Triple-Negative Breast Cancer
Status: Active
Location: Icahn School of Medicine at Mount Sinai, New York, New York
Chimeric HER2 B-cell Peptide Vaccine Emulsified in Montanide ISA 720 for the Treatment of High-Risk HER2 Positive Breast Cancer
Status: Active
Location: Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana
The Immune Effects of Fermented Wheat Germ Nutritional Supplementation in Patients with Solid Tumor Cancers Being Treated with Standard of Care Checkpoint Inhibitors
Status: Active
Location: 5 locations
Olaparib and Estradiol for the Treatment of Metastatic or Locally Recurrent ER+/HER2- Breast Cancer, PHOEBE Trial
Status: Active
Location: Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire
Dendritic Cell Vaccines against Her2/Her3 for the Treatment of Leptomeningeal Disease from Triple Negative Breast Cancer or HER2+ Breast Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Axatilimab with Low Dose Oral Cyclophosphamide and Retifanlimab for the Treatment of Locally Recurrent Unresectable and Metastatic Triple Negative Breast Cancer
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Status: Active
Location: Memorial Sloan Kettering Cancer Center, New York, New York
Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
Status: Active
Location: Dana-Farber - Harvard Cancer Center LAO, Boston, Massachusetts